Please login to the form below
Kisqali
This page shows the latest Kisqali news and features for those working in and with pharma, biotech and healthcare.
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
ruxolitinib) up by 26%, spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi) up by 28%, and cancer medicine Kisqali (ribociclib), which grew by 27% in sales revenue. ... Key innovation milestones in Q3 include Kisqali
Latest news
-
Strong five-year survival data for Kisqali in breast cancer
Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer. ... evaluating Kisqali compared to palbociclib in patients with HR+/HER2- advanced breast cancer with aggressive
-
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
Novartis also presented data from the phase 3 MONALEESA-3 trial analysing the efficacy and safety of Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with HR-positive/HER2-negative ... The updated analysis found that the need
-
Novartis' Kisqali shows long-term improvements in breast cancer patients
Kisqali plus fulvestrant also prolonged OS in the first- and second-line treatment subgroups. ... Our exploration of the benefits of Kisqali continues as we evaluate its potential in the adjuvant setting,” she added.
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
In addition, sales of the company’s plaque psoriasis treatment Cosentyx (secukinumab) increased by 7%, with its HER2-negative breast cancer therapy Kisqali (ribociclib) also growing by 50%.
-
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
According to NICE, Ibrance now joins two other of its approved drugs – Novartis’ Kisqali (ribociclib) and Lilly’s Verzenio (abemaciclib) - as a treatment option for patients at this stage of the
More from news
Approximately 9 fully matching, plus 28 partially matching documents found.
Subscribe to our email news alerts
- Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
No results were found
PMHub
Redbow Consulting Group
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
